pharma · Muscle-invasive bladder cancer (MIBC) · Acute ischaemic stroke due to basilar artery occlusion.
Tour Hekla
Tour Hekla clinical programs — 10 development programs from ClinicalTrials.gov with phase, modality, indication, and trial identifiers.
Company details
- Status
- Public
- HQ
- Puteaux, Ile de France 92800, FR
- Employees
- 6
- Programs
- 27
- Drugs
- 71
- Patents
- 0
Tour Hekla projects
10 ClinicalTrials.gov programs sponsored by Tour Hekla.
Tour Hekla has 10 clinical development programs indexed from ClinicalTrials.gov, including phase, modality, indication text, and linked NCT identifiers.
Clinical programs
-
DR200091
Tour Hekla
Thrombotic episodes in superficial venous malformations in children
1 trial -
DR230005
Tour Hekla
Patients with ventilator-associated tracheobronchitis
1 trial -
DR230297
Tour Hekla
Acute ischaemic stroke due to basilar artery occlusion.
1 trial -
DR230333
Tour Hekla
Intersitial lung disease related to systemic sclerosis
1 trial -
DR240020
Tour Hekla
Hypoxemic acute respiratory failure
1 trial -
FOSFOMYCIN , SULFAMETHOXAZOLE AND TRIMETHOPRIM
Tour Hekla
Benign Prostate Hyperplasia
1 trial -
PEDIADEX
Tour Hekla
Impact on delirium of the use of DEXmedetomidine as first-line sedation in PEDIAtric intensive care:
1 trial -
PHENOXYMETHYLPENICILLIN, PHENOXYMETHYLPENICILLIN
Tour Hekla
Recurrent Erysipelas in lower limbs
1 trial -
PROTO-BRAIN
Tour Hekla
Resistant Depression in the Elderly Subject
1 trial -
RIPH_2019_01
Tour Hekla
Adult with an staphylococcal prosthetic joint infection treated with debridement, antibiotics and implant retention (DAIR strategy)
1 trial
Frequently asked questions
How many clinical projects does Tour Hekla have?
10 published programs are linked to this sponsor in our ClinicalTrials.gov index.
Is this the complete company pipeline?
This directory lists published programs for the sponsor in our database. Partnered or out-licensed assets may appear under multiple companies.